Investigation of Profile-related Evidence Determining Individualized Cancer Therapy for Patients With Aggressive Malignancies and Poor Prognoses
Eligible age
18+ yrs
Accepts
All genders
Locations
1 state
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
This is a prospective, open-label navigational investigation designed to evaluate the feasibility of using molecular profile-based evidence to determine individualized cancer therapy for patients with aggressive malignancies. This is a non-randomized, histology-agnostic trial. Although there will be a case mix of histologies, the investigators now know that individual histologies are composed of a heterogeneous mix of molecular alterations. It is not clear whether one case mix is better or worse than another. Thus, the investigators are testing a strategy of molecular matching that may apply across different cancers.
Sponsor: Medical College of Wisconsin
You may qualify if…
- ✓ 1. Age ≥18 years.
- ✓ 2. Patient with aggressive solid malignancy must meet at least one of the following:
- ✓ 1. Malignancy with ≥30% two-year cancer-associated mortality as estimated by the treating oncologist and one of the study investigators and/or, where appropriate, according to accepted data sets in the field (e.g., NCDB). Diseases include but are not limited to: ampullary carcinoma, appendiceal cancer, colorectal cancer (CRC), extrahepatic cholangiocarcinoma (EHCC), esophageal adenocarcinoma, gallbladder cancer (GBCA) gastric adenocarcinoma, head and neck cancer, hepatocellular carcinoma (HCC), intrahepatic cholangiocarcinoma (IHCC), melanoma, non-KIT gastrointestinal stromal tumor (GIST), non-small cell lung cancer (NSCLC), ovarian cancer, pancreatic ductal adenocarcinoma (PDAC), sarcoma (high-grade), small bowel adenocarcinoma (including duodenal), triple-negative breast cancer (TNBC), urothelial cancer
- ✓ 2. Refused standard therapies, OR
- ✓ 3. Cancer of unknown primary or a rare tumor (i.e., fewer than 4 cases per 100,000 per year) with no approved therapies.
- ✓ 3. Patient with aggressive solid malignancy irrespective of two-year mortality who, in the opinion of the investigator, has no treatment option expected to yield significant clinical benefit.
- ✓ 4. Patient must have at least one of the following for a diagnosis/disease status:
- ✓ 1. Unresectable disease, as determined by a disease-appropriate multidisciplinary tumor board.
You may not qualify if…
- ✕ A potential study subject who meets any of the following exclusion criteria is ineligible to participate in the study.
- ✕ 1. Two oncologists disagree on prognosis or resectability.
- ✕ 2. Severe or uncontrolled medical disorder that would, in the investigator's opinion, confound study analyses of treatment response (i.e., uncontrolled diabetes, chronic renal disease, chronic pulmonary disease or active, uncontrolled infection, psychiatric illness/social situations that would limit compliance with study requirements).
- ✕ 3. Is pregnant or breastfeeding or any patient with childbearing potential not using adequate pregnancy prevention.
- ✕ 4. Whole brain radiation or stereotactic radiotherapy to CNS metastases within 14 days prior to start of study treatment.
Where it's recruiting
Milwaukee
Source: ClinicalTrials.gov · NCT05674825 · last updated 2026-05-22